Glyset: Advanced Glycemic Control for Type 2 Diabetes
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.62 | $78.70 (0%) | 🛒 Add to cart |
| 60 | $1.97 | $157.40 $118.05 (25%) | 🛒 Add to cart |
| 90 | $1.75
Best per pill | $236.10 $157.40 (33%) | 🛒 Add to cart |
Synonyms | |||
Glyset (miglitol) is an alpha-glucosidase inhibitor designed to manage blood glucose levels in adults with type 2 diabetes mellitus. It functions by delaying the digestion of carbohydrates in the small intestine, thereby reducing postprandial hyperglycemia. When used as part of a comprehensive treatment plan—including diet, exercise, and potentially other antidiabetic agents—Glyset offers a targeted mechanism to improve glycemic control without stimulating insulin secretion. It is particularly beneficial for patients who experience significant glucose spikes following meals and require a non-systemic approach to moderation.
Features
- Active ingredient: Miglitol 25mg, 50mg, or 100mg tablets
- Drug class: Alpha-glucosidase inhibitor
- Administration: Oral tablet
- Onset of action: Begins with the first meal following administration
- Duration: Effects persist for the duration of carbohydrate digestion
- Prescription status: Rx-only in most jurisdictions
Benefits
- Reduces postprandial blood glucose excursions by inhibiting carbohydrate breakdown
- Lowers HbA1c levels through consistent mealtime glucose modulation
- Does not cause hypoglycemia when used as monotherapy
- Minimally absorbed systemically, reducing risk of systemic adverse effects
- Compatible with other antidiabetic regimens including sulfonylureas or insulin
- Supports long-term glycemic goals without weight gain
Common use
Glyset is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is especially useful in patients whose postprandial glucose levels are disproportionately elevated compared to fasting levels. It may be used as monotherapy or in combination with other oral antidiabetic agents or insulin when glycemic targets are not achieved with lifestyle modifications alone.
Dosage and direction
The recommended starting dose of Glyset is 25 mg taken orally three times daily at the start of each main meal. The dose may be increased after 4–8 weeks to 50 mg three times daily based on tolerability and glycemic response. Further titration to 100 mg three times daily may be considered for patients who tolerate the lower doses but require additional glycemic control. Tablets should be swallowed whole with a small amount of liquid at the beginning of the meal. Dosage adjustments may be necessary in patients with renal impairment.
Precautions
- Gastrointestinal side effects such as flatulence, diarrhea, and abdominal discomfort are common, especially during initiation. These often diminish with continued use.
- Not recommended for patients with inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction due to its local action.
- Use with caution in patients with renal impairment (creatinine clearance <25 mL/min); miglitol is excreted renally.
- Monitor liver function periodically, although hepatotoxicity is rare.
- May reduce serum iron levels; periodic monitoring may be advisable in at-risk populations.
Contraindications
- Hypersensitivity to miglitol or any component of the formulation.
- Diabetic ketoacidosis.
- Inflammatory bowel disease, colonic ulceration, or chronic intestinal diseases associated with marked disorders of digestion or absorption.
- Conditions that may deteriorate as a result of increased gas formation in the intestine.
Possible side effects
Most common adverse reactions are related to the gastrointestinal system and result from carbohydrate fermentation in the colon:
- Flatulence (~42%)
- Diarrhea (~29%)
- Abdominal pain (~12%)
- Rash (~4%) Less commonly reported:
- Elevated serum transaminases
- Reduced serum iron levels
Drug interaction
- May reduce the bioavailability of digoxin, propranolol, and ranitidine; administer these drugs at least 2 hours before or after Glyset.
- Should not be taken with digestive enzyme preparations containing carbohydrate-splitting enzymes (e.g., amylase, pancreatin), as these may reduce Glyset’s efficacy.
- Other hypoglycemic agents (e.g., sulfonylureas, insulin) may increase the risk of hypoglycemia when used concomitantly.
Missed dose
If a dose is missed, it should be omitted and the next dose taken at the usual time with the next meal. Do not double the dose.
Overdose
An overdose may result in transient increases in flatulence, diarrhea, and abdominal discomfort. Hypoglycemia has not been reported with miglitol overdose. There is no specific antidote; treatment should be symptomatic and supportive. Hemodialysis may remove circulating miglitol.
Storage
Store at room temperature (20–25°C or 68–77°F) in a dry place. Protect from light and moisture. Keep out of reach of children. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is intended for healthcare professionals and should not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. Do not disregard professional medical advice or delay in seeking it because of something you have read in this document.
Reviews
Glyset has been evaluated in multiple clinical trials demonstrating its efficacy in reducing postprandial glucose and HbA1c. In a 1-year placebo-controlled study, miglitol 100 mg three times daily reduced HbA1c by an average of 0.7% compared to placebo. Patient satisfaction is often tied to gastrointestinal tolerability, which improves over time. It remains a valued option for patients seeking a non-insulin-stimulating, meal-focused glycemic control agent.